BI 1467335

Drug Profile

BI 1467335

Alternative Names: PXS 4728A

Latest Information Update: 06 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmaxis
  • Developer Boehringer Ingelheim; Pharmaxis; University of Sydney
  • Class Anti-inflammatories; Hepatoprotectants; Recombinant fusion proteins; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic retinopathy; Non-alcoholic steatohepatitis
  • Phase I Chronic obstructive pulmonary disease; Cystic fibrosis
  • Preclinical Asthma; Renal fibrosis

Most Recent Events

  • 16 Aug 2018 Boehringer Ingelheim completes a phase I pharmacokinetic trial in healthy volunteers and patients with moderate renal impairment in Germany (NCT03302091)
  • 24 Jun 2018 Biomarkers information updated
  • 05 Jun 2018 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Netherlands (PO) (NCT03483506)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top